Shortly after trading begins, we will sell 10 shares of Eli Lilly at around $958 each. After Monday's trading, Jim Cramer's Charitable Trust will own 100 shares of LLY, reducing its weight from approximately 3.13% to 2.85%. Now that we're no longer constrained, we're selling some shares of Eli Lilly. We downgraded Lilly stock to our 2 rating last Tuesday as it rallied to a new all-time high. We had previously upgraded Lilly to our 1 Buy rating in the mid-$800s in July when the stock fell on concerns about competition in the fast-growing GLP-1 class of diabetes (Mounjaro) and weight-loss (Zepbound) drugs. Those concerns quickly proved overbought after the company's second-quarter earnings report, which cemented its leadership position in GLP-1 with improved supply. LLY 1Y Berg Eli Lilly YTD But this reduction is all about discipline. We've let the stock run for almost a full year. Our previous sale was in September 2023 at $591. With Lilly shares up more than 60% since then, we don't want to catch ourselves being too greedy. We're about to make a fantastic 288% gain on the shares we bought in January 2022. (Jim Cramer's Charitable Trust is long LLY. You can find a full list of stocks here.) As a subscriber to CNBC Investing Club with Jim Cramer, you'll receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock from his charitable trust's portfolio. If Jim has discussed a stock on CNBC television, he waits 72 hours after the trade alert is issued before executing the trade. THE INVESTING CLUB INFORMATION DESCRIBED ABOVE IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY AND OUR DISCLAIMER. NO FIDUCIARY OBLIGATION OR DUTY EXISTS OR IS CREATED BY RECEIVING INFORMATION RELATED TO THE INVESTING CLUB. NO PARTICULAR RESULT OR PROFIT IS GUARANTEED.
Categories
We make virtually 300% revenue with a sizzling pharmaceutical inventory
